

Accepted Manuscript

Title: The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Author: Robert Roskoski Jr.

PII: S1043-6618(18)30599-1
DOI: <https://doi.org/10.1016/j.phrs.2018.04.020>
Reference: YPHRS 3886

To appear in: *Pharmacological Research*

Received date: 23-4-2018
Accepted date: 23-4-2018

Please cite this article as: Roskoski Robert. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. *Pharmacological Research* <https://doi.org/10.1016/j.phrs.2018.04.020>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Robert Roskoski Jr.

Blue Ridge Institute for Medical Research

3754 Brevard Road, Suite 116, Box 19

Horse Shoe, North Carolina 28742-8814, United States

Phone: 1-828-891-5637

Fax: 1-828-890-8130

E-mail address: rrj@brimr.org

Keywords;

Chemical compounds studied in this article: Axitinib: (PubMed CID: 6450551); Cabozantinib (PubMed CID: 25102847); Dasatinib: (PubMed CID: 3062316); Imatinib: (PubMed CID: 5291); Lenvatinib: (PubMed CID: 9823820); Midostaurin: (PubMed CID: 9829523); Ponatinib: (PubMed CID: 24826799); Regorafenib: (PubMed CID: 11167602); Sorafenib: (PubMed CID: 216239); Sunitinib: (PubMed CID: 5329102)

Abbreviations: AS, activation segment; CS or C-spine, catalytic spine; CL, catalytic loop; CTT, carboxyterminal tail; D1, immunoglobulin-like domain-1; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumors; GK, gatekeeper; GRL, Gly-rich loop; KD, kinase domain; KID, kinase insert domain; JM, juxtamembrane; PDGFR, platelet-derived growth factor receptor; PKA, protein kinase A; Ph⁺, Philadelphia chromosome positive; PKC, protein kinase C; pY or pTyr, phosphotyrosine; RS or R-spine, regulatory spine; Sh2, shell residue 2; TM, transmembrane, VEGFR, vascular endothelial growth factor receptor.

Graphical Abstract

Download English Version:

<https://daneshyari.com/en/article/8536306>

Download Persian Version:

<https://daneshyari.com/article/8536306>

[Daneshyari.com](https://daneshyari.com)